United Therapeutics CORP Form 4 insider transactions

United Therapeutics Corp's President and COO, Michael Benkowitz, exercised stock options and sold a portion of the resulting common stock through pre-arranged trading plans.

United Therapeutics Director Jan Malcolm sold 700 shares of common stock for $400.29 per share, reducing her direct beneficial ownership to 520 shares.

United Therapeutics CEO Martine Rothblatt exercised stock options and sold common stock as part of a pre-arranged 10b5-1 trading plan.

United Therapeutics Director Tommy G. Thompson exercised stock options and subsequently sold 4,560 shares of common stock on September 10, 2025.

Paul A. Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold 11,000 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics' President and COO, Michael Benkowitz, executed pre-planned sales of common stock totaling 22,500 shares after exercising stock options, alongside an additional disposal of 2,648 shares.

United Therapeutics Director Christopher Causey exercised stock options and sold 3,000 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics' EVP & General Counsel, Paul A. Mahon, exercised stock options and subsequently sold 11,000 shares of common stock under a pre-arranged 10b5-1 plan.

United Therapeutics EVP & General Counsel Paul A. Mahon exercised stock options and sold 11,000 shares for approximately $3.3 million under a pre-arranged 10b5-1 plan.

United Therapeutics Director Tommy G Thompson received an annual award of 3,650 stock options with an exercise price of $306.41.

United Therapeutics director Christopher Patusky reported the vesting of restricted stock units and the acquisition of new equity awards.

United Therapeutics Director Judy D. Olian reported the vesting of 1,190 restricted stock units into common stock and the grant of 1,310 new restricted stock units.

United Therapeutics Director Nilda Mesa reported the vesting of restricted stock units and new equity awards, including stock options and additional restricted stock units.

United Therapeutics director Linda Maxwell was granted 3,650 stock options as part of an annual non-employee director award.

United Therapeutics Director Ray Kurzweil reported the vesting of restricted stock units and the acquisition of new equity awards.

United Therapeutics Director Richard Giltner reported the vesting of 1,190 restricted stock units and the award of 1,310 new restricted stock units.

United Therapeutics Director Louis W. Sullivan increased his beneficial ownership through RSU vesting and new equity awards, signaling continued alignment with shareholder interests.

United Therapeutics Corp director Raymond Dwek was granted 3,650 stock options as part of an annual non-employee director award, exercisable from July 9, 2026.

United Therapeutics Director Christopher Causey reported the vesting of restricted stock units and the grant of new stock options.

United Therapeutics Corporation Director Jan Malcolm reported the vesting of restricted stock units and the grant of new equity awards, including stock options and additional restricted stock units.

Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corporation, exercised stock options and subsequently sold an equivalent number of shares as part of a pre-arranged trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp., executed a planned exercise of stock options and subsequent sale of common shares on July 10, 2025, as disclosed in a recent SEC Form 4 filing.

Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp, completed a pre-arranged exercise of stock options and subsequent sale of common stock totaling 11,000 shares on June 26, 2025.

Nilda Mesa, a Director at United Therapeutics Corp (UTHR), reported the sale of 645 shares of common stock for approximately $289.99 per share under a Rule 10b5-1 plan.

A director at United Therapeutics Corp. exercised stock options and subsequently sold a portion of the acquired shares in a cashless transaction.

Paul A. Mahon, Executive Vice President and General Counsel of United Therapeutics Corp., exercised stock options and sold the resulting shares totaling 11,000 under a pre-arranged 10b5-1 plan.

United Therapeutics Corporation's CFO and Treasurer, James Edgemond, exercised stock options and sold 12,000 shares of common stock on June 9, 2025, as part of a pre-arranged 10b5-1 trading plan.

James Edgemond, CFO and Treasurer of United Therapeutics Corp (UTHR), exercised stock options and subsequently sold common stock shares on June 2, 2025, as part of a pre-arranged 10b5-1 trading plan.

Paul A. Mahon, EVP & General Counsel of United Therapeutics Corp., exercised stock options and simultaneously sold 11,000 shares of common stock for approximately $3.47 million under a pre-arranged 10b5-1 plan.

Paul Mahon, EVP & General Counsel of United Therapeutics, exercised stock options and sold shares on May 15, 2025, according to a pre-arranged 10b5-1 plan.